Literature DB >> 9391285

Long-term follow up of patients with implantable cardioverter-defibrillators and mild, moderate, or severe impairment of left ventricular function.

H J Trappe1, P Wenzlaff, P Pfitzner, H G Fieguth.   

Abstract

OBJECTIVE: To determine whether patients with life threatening ventricular tachyarrhythmias, impaired left ventricular function, and severe heart failure will benefit from implantable cardioverter-defibrillator (ICD) treatment.
DESIGN: 410 patients were followed up after ICD implant. Left ventricular function was assessed by the New York Heart Association (NYHA) functional class of heart failure: 50 patients (12%) were in NYHA I-II, 151 (37%) in NYHA II, 117 (29%) in NYHA II-III, and 92 (22%) in NYHA III. Epicardial ICD implantation was performed in 209 patients (51%) and 201 patients (49%) received non-thoracotomy ICDs.
RESULTS: Perioperatively, 12 patients (3%) died, more often after epicardial ICD implant (11/209 patients, 5%) than after transvenous implant (1/201 patients, < 1%) (P < 0.05). During a mean (SD) follow up of 28 (24) months (range < 1 to 114 months), 90 patients (23%) died: nine (2%) died from sudden arrhythmia; five (1%) also died suddenly but probably not from arrhythmic causes; 55 (14%) died from cardiac causes (congestive heart failure, myocardial reinfarction); 21 (5%) died from non-cardiac causes. The three year, five year, and seven year survival was 92-96% for arrhythmic mortality in NYHA class I, II and III, compared to a three year survival of 94% and a five year and seven year survival of 84% for patients in NYHA class II-III. 338 patients (82%) received ICD shocks (21 (SD 43) shocks per patient); patients in NYHA class II (83%), class II-III (84%), and class III (90%) received ICD discharges more often than those in class I-II (64%) (P < 0.05). The mean (SD) time interval between ICD implant and the first ICD shock was shorter in NYHA class II (16 (17) months), class II-III (19 (27) months), and class III (16 (19) months) than in class 0-I (22 (24) months) (P < 0.05).
CONCLUSIONS: Patients with mild, moderate, and severe left ventricular dysfunction benefit from ICD treatment and these patients survive for a considerable time after the first shock. Survival is influenced by the degree of left ventricular dysfunction; aggressive treatment of heart failure is necessary as well as ICD therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9391285      PMCID: PMC484925          DOI: 10.1136/hrt.78.3.243

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  22 in total

1.  Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome.

Authors:  D J Wilber; H Garan; D Finkelstein; E Kelly; J Newell; B McGovern; J N Ruskin
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

2.  AICD benefit.

Authors:  S Furman
Journal:  Pacing Clin Electrophysiol       Date:  1989-03       Impact factor: 1.976

3.  AICD automatic cardioverter defibrillator clinical update: 14 years experience in over 34,000 patients.

Authors:  S Nisam; S A Kaye; M M Mower; M Hull
Journal:  Pacing Clin Electrophysiol       Date:  1995-01       Impact factor: 1.976

4.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy.

Authors:  J A Franciosa; M Wilen; S Ziesche; J N Cohn
Journal:  Am J Cardiol       Date:  1983-03-01       Impact factor: 2.778

5.  Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias.

Authors:  P J Tchou; N Kadri; J Anderson; J A Caceres; M Jazayeri; M Akhtar
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

6.  Determinants of survival in patients with ventricular tachyarrhythmias.

Authors:  C D Swerdlow; R A Winkle; J W Mason
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

7.  Sudden coronary death in the United States: 1980-1985.

Authors:  R F Gillum
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

8.  Nonpharmacological therapy of ventricular tachyarrhythmias: observations in 554 patients.

Authors:  H J Trappe; P Pfitzner; H G Figuth; P Wenzlaff; B Kielblock; H Klein
Journal:  Pacing Clin Electrophysiol       Date:  1994-11       Impact factor: 1.976

9.  Role of antitachycardia pacing in patients with third generation cardioverter defibrillators.

Authors:  H J Trappe; H Klein; B Kielblock
Journal:  Pacing Clin Electrophysiol       Date:  1994-03       Impact factor: 1.976

10.  Cardioverter defibrillator therapy as a bridge to heart transplantation.

Authors:  H J Trappe; P Wenzlaff
Journal:  Pacing Clin Electrophysiol       Date:  1995-03       Impact factor: 1.976

View more
  3 in total

Review 1.  [Cardiology update. I: Electrophysiology].

Authors:  P Weismüller; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-01-15

2.  Automatic measurement of long-term heart rate variability by implanted single-chamber devices.

Authors:  M Malik; V Padmanabhan; W H Olson
Journal:  Med Biol Eng Comput       Date:  1999-09       Impact factor: 2.602

3.  The use of implantable cardioverter defibrillators in Iceland: a retrospective population based study.

Authors:  Margret Leosdottir; Gudrun Reimarsdottir; Gizur Gottskalksson; Bjarni Torfason; Margret Vigfusdottir; David O Arnar
Journal:  BMC Cardiovasc Disord       Date:  2006-05-24       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.